Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

Foundation Medicine
→
Roche

Acquisition · Cash · ROG · announced Jun 19, 2018

View in network
  1. Announced

    Jun 19, 2018

  2. Closed

    Jul 18, 2018

Economics

Cash()

Pre-deal · pre-deal mark: 2018, year precision · rounding grid ±$100M · Roche 8-K filing, SEC EDGAR — Foundation Medicine acquisition

$137/share for remaining shares (~$2.4B); total company value ~$5.3B fully diluted

Target

Foundation Medicine

Precision Medicine · Diagnostic / genomic

HQ Cambridge, MA · Founded 2010

Last known · fully diluted · Total company value ~$5.3B fully diluted; Roche paid ~$2.4B for remaining shares (Roche press release, Jun 2018)

Comprehensive genomic profiling (CGP) for cancer — FoundationOne tests guide precision treatment including breast and ovarian cancer

  • Roche media release (Jun 19, 2018)
  • Fierce Biotech - deal coverage
  • SEC EDGAR - 10-K filing (CIK 0001573773, ticker FMI)

Acquirer

Roche (ROG)

Precision Medicine

HQ Basel, Switzerland

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Comprehensive genomic profiling (CGP) — FoundationOne tests identify actionable mutations in breast, ovarian, and other cancers to guide precision treatment selection

Evidence ladder

Press only — no primary filingValue disclosed
  1. Tertiary (trade / analyst)

    Roche media release (Jun 19, 2018)

  2. Secondary (press / IR)

    Fierce Biotech

Limitations

  • Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
  • $137/share for remaining shares (~$2.4B); total company value ~$5.3B fully diluted
  • Pre-deal valuation sourced from: Roche 8-K filing, SEC EDGAR — Foundation Medicine acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.

Valuation peers · Precision Medicine

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Why included
Genomic HealthExact SciencesJul 29, 2019same evidence class
GRAILIlluminaSep 21, 2020same evidence class
Flatiron HealthRocheJan 8, 2018same acquirer

Same-sector adjacency — not valuation peers

These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.

Vs this deal
Varian Medical SystemsSiemens HealthineersAug 2, 2020

Other verified deals by Roche

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by Roche are already listed above, or none are in the dataset.

Patient empowerment context

Empowerment context — Foundation Medicine

Curated survey mapping

HLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.

  • Not recommended genetic testing (NCCN: almost all should) (Company / product site)37%cited HLTH 2022Mapping source →
  • Presented with clinical trial as treatment option (Company / product site)1 in 5cited HLTH 2022Mapping source →
  • No survivorship care plan after active treatment (Company / product site)54%cited HLTH 2022Mapping source →

Other curated mappings on these gaps: Biotheranostics, Endomagnetics, Genomic Health, Flatiron Health

Full cited gap matrix →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.